Can Ozempic prevent cancer? Several large studies suggest it might. But the excitement is running ahead of the evidence. In @theconversation.com, I explain what the evidence actually shows and why these studies are so easy to misread. theconversation.com/can-ozempic-...

Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread

Several studies suggest GLP-1 drugs may lower cancer risk. But that benefit may be due to the patients themselves: those who are healthier, wealthier and with better access to care.

theconversation.com

The finding that stopping GLP-1 drugs can undo years of heart protection is resonating. Coverage from CNN, TIME, USA Today, CNBC, Gizmodo, and others. What 3 years of continuous treatment builds, ~1.5 years off the drug can erase.

What happens to the heart when people stop GLP-1 drugs? The short answer: nothing good. 333,000+ adults. 3 years. 16 treatment scenarios. New in @bmjmedicine.bsky.social 🧵

I joined Dr. Susan Kuo from @longcovidcan-co.bsky.social to talk about Long COVID — what we've learned, where we are, and what's ahead. youtu.be/T3WD-tTFSWQ

Long Covid: Past, Present and Future – ft. Dr. Ziyad Al-Aly

YouTube video by Canadian Covid Society

youtu.be

For your weekend reading: I wrote about what our BMJ findings mean for addiction — why GLP-1s work across every addictive substance, and how these drugs seem to quiet cravings the same way they quiet food noise. @us.theconversation.com theconversation.com/glp-1-drugs-...

GLP-1 drugs may fight addiction across every major substance, according to a study of 600,000 people

GLP-1 drugs are the first medication to show promise for treating addiction to a wide range of substances.

theconversation.com

New in the BMJ: Our study of 600,000 people found GLP-1 drugs associated with 50% fewer substance-related deaths, 39% fewer overdoses, and reduced addiction risk across alcohol, opioids, cocaine, cannabis, and nicotine. www.bmj.com/content/392/...

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study

Objectives To investigate whether initiation of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with both reduced risks of incident alcohol, cannabis, cocaine, nicotine, opioid, and ot...

bmj.com

Please help us spread the word. We are hiring postdoctoral fellows in Clinical Epidemiology and Pharmacoepidemiology. Details and application via Indeed.

Postdoctoral Fellow - St. Louis, MO 63106 - Indeed.com

Veterans Research and Education Foundation of St. Louis

indeed.com

Honored to speak at Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing forward!!!

For decades, the junk food industry has deliberately engineered foods to be addictive. GLP-1 drugs have helped people break free from this cycle. The industry is now searching for ways to undo the effects of these meds, aiming to design foods that remain addictive for those on GLP1. buff.ly/40QHDnk

Ozempic Could Crush the Junk Food Industry. But It Is Fighting Back.

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

nytimes.com

GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction.

Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine

An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic…

buff.ly

New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. www.nordforsk.org/2025/knowled...

Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @theconversation.com @france.theconversation.com theconversation.com/alzheimer-ad...

Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés

Les médicaments GLP-1 sont efficaces pour traiter le diabète et l’obésité. Ils pourraient l’être aussi pour lutter contre de nombreuses autres affections. Néanmoins, des effets indésirables existent.

theconversation.com

I talked to Dani Blum from @nytimes.com about the potential role of GLP-1 drugs (Ozepmic and similar drugs) on Alzheimer’s disease. They seem promising, but more data is needed. www.nytimes.com/2025/01/31/w...

Could Ozempic Protect Against Alzheimer’s?

Could a diabetes and weight loss drug benefit the brain? Here’s what scientists are learning.

nytimes.com

🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. www.nature.com/articles/s41...

Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine

An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...

nature.com

📄 Free access to the full study: rdcu.be/d6VYU New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (e.g. Ozempic and similar weight loss drugs) across 175 health conditions. Please share and download before it goes back behind paywall.

Mapping the effectiveness and risks of GLP-1 receptor agonists

Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...

rdcu.be

The latest from my team in Nature Medicine. We comprehensively mapped the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me A 🧵 www.nature.com/articles/s41...

Mapping the effectiveness and risks of GLP-1 receptor agonists - Nature Medicine

An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other antihyperglycemic medicat...

nature.com

My first post has to be about #LongCOVID 🔹 400 million individuals affected worldwide 🔹 $1 trillion in annual economic costs 🔹 Countless lives & communities shattered The time for a comprehensive policy and research response is now! Details in our review here www.nature.com/articles/s41...

Long COVID science, research and policy - Nature Medicine

This Review outlines the current state of scientific evidence on long COVID, discusses its impacts on patients, health systems, economies and global health metrics, and proposes a forward-looking rese...

nature.com